403
Views
52
CrossRef citations to date
0
Altmetric
Growth Factor Signaling and Radiotherapy to Encompass Both EGFR and TGFβ

New rationales for using TGFbeta inhibitors in radiotherapy

, , &
Pages 803-811 | Received 12 Jul 2007, Accepted 24 Sep 2007, Published online: 03 Jul 2009
 

Abstract

Purpose: The first reports that ionizing radiation (IR) induces rapid and persistent activation of transforming growth factor β1 (TGFβ) were nearly two decades ago. Subsequent studies have shown that TGFβ is a major mediator of cellular and tissue responses to IR and have revealed novel facets of its complex biology.

Results: We and others have recently shown that inhibition of production or signaling of TGFβ in epithelial cells modulates radiosensitivity and impedes activation of the DNA damage response program. The primary transducer of cellular response to DNA damage caused by ionizing radiation is the nuclear protein kinase ataxia telangiectasia mutated, whose activity is severely compromised when TGFβ is inhibited. Thus, in conjunction, with its well-recognized contribution to normal tissue fibrosis, the role of TGFβ in the genotoxic stress program provides a previously unsuspected avenue to modulate radiotherapy.

Conclusions: We hypothesize that identification of the circumstances and tumors in which TGFβ manipulation enhances tumor cell radiosensitivity, while protecting normal tissues, could significantly increase therapeutic index.

Abbreviations
TGFβ=

Transforming growth factor β

LTGFβ=

Latent transforming growth factor β

ATM=

Ataxia telangiectasia mutated

IR=

Ionizing radiation

RT=

Radiotherapy

TβRIKI=

TGFβ receptor type I kinase inhibitor

LAP=

Latency associated peptide

ROS=

Reactive oxygen species

Abbreviations
TGFβ=

Transforming growth factor β

LTGFβ=

Latent transforming growth factor β

ATM=

Ataxia telangiectasia mutated

IR=

Ionizing radiation

RT=

Radiotherapy

TβRIKI=

TGFβ receptor type I kinase inhibitor

LAP=

Latency associated peptide

ROS=

Reactive oxygen species

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.